Key facts
- KYAN Technologies’s last known valuation is $18.1M (Jun 2025).
- It has raised $8.2M; the latest was Later Stage VC ($3.2M) in Jun 2025.
- Notable investors include SEEDS Capital, K3 Ventures, RNT Associates, Altara Ventures, Enterprise Singapore.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for KYAN Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for KYAN Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KYAN Technologies
Developer of functional precision medicine technology designed to bridge the cancer care gap by advancing technologies. The company's technology identifies safe and useful drug-dose combinations based on small inputs of data, as well as transforms the way patients are treated and therapies are developed, enabling the medical industry to create multiple drugs in the field of oncology and infectious diseases.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2016
- Employees
- 6
- Website
- kyantechnologies.com/
- Ownership
- Privately Held (backing)
KYAN Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KYAN Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KYAN Technologies in its N-PORT filings yet. We sweep new filings monthly.